The CAR-HEMATOTOX Risk-Stratifies Patients for Severe Infections and Disease Progression after CD19 CAR-T in R/R LBCL.

TY - JOUR

T1 - The CAR-HEMATOTOX Risk-Stratifies Patients for Severe Infections and Disease Progression after CD19 CAR-T in R/R LBCL.

AU - Perez Perez, Ariel

AU - and institutional affiliations, Additional authors

N1 - These data demonstrate the utility of the HT score to risk-stratify patients for infectious complications and poor survival outcomes prior to CD19 CAR-T. High-risk patients likely benefit from anti-infective prophylaxis and should be closely monitored for potential infections and relapse.

PY - 2022/5

Y1 - 2022/5

UR - https://pubmed.ncbi.nlm.nih.gov/35580927/

M3 - Article

JO - Journal for Immunotherapy of Cancer

JF - Journal for Immunotherapy of Cancer

ER -